Efficacy and Safety of SR58611A co-Administered With Escitalopram in Adults With Major Depressive Disorder

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2007
The primary objective of the study is to compare, after 8 weeks, the efficacy of SR58611A vs. placebo in patients with Major Depressive Disorder who are on concomitant treatment with escitalopram. The secondary objective of this study is to document clinical safety and tolerability of SR58611A in association with escitalopram.
Epistemonikos ID: 19cc35ff32d7020b7feeab62dc63c608c2911dc7
First added on: May 04, 2024